Drug Trial Radar · NCT05757102
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Apr 24, 2023
Primary completion
Jan 26, 2027
Study completion Jan 28, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Conditions
- Asthma
Interventions
FF/UMEC/VIDrug
FF/UMEC/VI will be administered.
ELLIPTADevice
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
FF/VIDrug
FF/VI will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24Time frame: Baseline (Week 0) and Week 24
Locations
67 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Paradise Valley, Arizona
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Mission Viejo, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
Plano, Texas
GSK Investigational Site
Waco, Texas
GSK Investigational Site
Milwaukee, Wisconsin
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Córdoba, Argentina
GSK Investigational Site
Lanus, Argentina
GSK Investigational Site
Lobos, Argentina
GSK Investigational Site
Lujan de Cuyo, Argentina
GSK Investigational Site
Mar del Plata, Argentina
GSK Investigational Site
Rosario, Argentina
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.